AzTrials
AzTrials

Cardiac Arrest, Out-Of-HospitalVICAP-CPRNCT07026773

Validity of ICU Clinician's Appraisal of Proportionality in CPR

An observational study of Cardiac Arrest, Out-Of-Hospital, run by University Hospital, Ghent at 9 sites in 8 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The VICAP-CPR study investigates whether doctors and nurses working in Intensive Care can determine neurological outcome and future quality of life after six months in patients treated for cardiac arrest outside the hospital based on clinical assessment in the first 24 hours after admission to Intensive Care. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cardiac Arrest, Out-Of-Hospital
How many people
1,000 participants
Where
9 sitesin 8 countries
Study dates
18 May 2025to 30 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population are doctors and nurses working in an Intensive Care Unit treating a patient included in the STEPCARE study (NCT 05564754) during the first 24 hours after admission to Intensive Care

Who may be able to join

  • Doctors and nurses working in the Intensive Care Unit treating patients included in the STEPCARE study (NCT 05564754)

Who cannot join

  • Doctors and nurses who do not have a direct treatment relationship with a patient included in the STEPCARE study

Trial locations and contacts

9 sites in 8 countries. Contact the study team or a site near you to ask about taking part.

Patrick Druwé, MD, PhD contact

003293321387

patrick.druwe@uzgent.be

Daisy Vermeiren, Research Nurse contact

003293320508

patrick.druwe@uzgent.be

9 sites in 8 countries

Belgium2 sites, 2 recruiting
  • Ziekenhuis Oost-Limburg

    Genk, 3600

    Koen Ameloot, MD, 003289807251, koen.ameloot@zol.be

    Recruiting
  • Ghent University Hospital

    Ghent, 9000

    Patrick Druwé, MD PhD, 003293321387, patrick.druwe@uzgent.be

    Recruiting

Other trials in Belgium

Austria1 site, 1 recruiting
  • Medical University Innsbruck

    Innsbruck, 6020

    Michael Joannidis, MD PhD, michael.joannidis@i-med.ac.at

    Not yet recruiting

Other trials in Austria

Finland1 site, 1 recruiting
  • Helsinki University Central Hospital

    Helsinki, 000290

    Markus Skrifvars, MD PhD, Markus.Skrifvars@hus.fi

    Not yet recruiting

Other trials in Finland

Germany1 site, 1 recruiting
  • Universitätsklinikum Lübeck

    Lübeck, 23538

    Tobias Graf, MD, Tobias.Graf@uksh.de

    Recruiting

Other trials in Germany

Italy1 site, 1 recruiting
  • Policlinico San Martino

    Genova, 16149

    Chiara Robba, MD PhD, kiarobba@gmail.com

    Recruiting

Other trials in Italy

New Zealand1 site, 1 recruiting
  • Wakefield Hospital

    Wellington, 6021

    Paul Young, MD PhD, paul.young@ccdhb.org.nz

    Recruiting

Other trials in New Zealand

Saudi Arabia1 site, 1 recruiting
  • King Abdulaziz Medical City

    Riyadh, 22490

    Yaseen Arabi, MD PhD, yaseenarabi@yahoo.com

    Recruiting

Other trials in Saudi Arabia

Switzerland1 site, 1 recruiting
  • Zürich University Hospital

    Zurich, 8091

    Matthias Hilty, Matthias.Hilty@usz.ch

    Not yet recruiting

Other trials in Switzerland

About this study

The VICAP-CPR study investigates whether doctors and nurses working in Intensive Care can determine neurological outcome and future quality of life after six months in patients treated for cardiac arrest outside the hospital based on clinical assessment in the first 24 hours after admission to Intensive Care. To conduct this study, the results of the questionnaire offered to Intensive Care doctors and nurses regarding the estimation of long-term neurological outcome and quality of life will be compared with the neurological outcome and quality of life as recorded in the STEPCARE study (NCT 05564754). The aim of the international STEPCARE study is to determine the best combination of post-resuscitation care to favourably influence survival and neurological outcome in patients treated for cardiac arrest outside hospital.

Read the detailed description

In the guidelines 2021 of the European Resuscitation Council it is acknowledged that apart from criteria related to the cardiac arrest circumstances, additional criteria can be used to support resuscitation decisions. For instance, the presence of severe chronic comorbidities or a very poor quality of life prior to cardiac arrest are allowed to support decisions to stop or not start resuscitation in unwitnessed out-of-hospital cardiac arrest (OHCA) with an initial non-shockable rhythm. In current clinical practice, these factors are often not taken into account and patients with severe underlying comorbidities and poor general condition are also resuscitated. In intensive care, a wait-and-see approach is then usually adopted until additional information is gathered about the patient's likely prognosis based on repetitive clinical neurological examination, electrophysiological tests such as electro-encephalography and somatosensory evoked potentials, biomarker analysis and cerebral imaging (multimodal neuroprognostication).

At the ICU level, both physicians and nurses can have valuable insights into what the likely prognosis is of the OHCA patients they are treating. In subgroups with a poor prognosis (e.g. non-shockable unwitnessed arrest in older patient) the added value of the multimodal ICU neuroprognostication is potentially very limited or absent. The implication for intensive care could be that policy decisions could perhaps be made earlier in several situations. Exploring the prognostic value of the clinical perception of ICU physicians and ICU nurses regarding appropriateness of CPR and their prognostication of neurological outcome and quality of life relative to multimodal ICU neuroprognostication might help to refine the ethical guidance towards resuscitation decision making and towards ICU management after ROSC in general.

The study aims are:

  1. To assess whether and to what extent the following factors are associated with ICU clinician's perception regarding appropriateness of CPR: perceived presence of frailty, poor quality of life and severe comorbidities, as well as objective factors related to the OHCA (shockable rhythm, bystander CPR, witnessed arrest) and clinician characteristics (age, gender, years of experience and professional background).
  2. To assess the concordance between clinicians' combined perception of inappropriateness of CPR (i.e. whether or not at least 2 clinicians perceive CPR as inappropriate) and multimodal ICU neuroprognostication as performed in STEPCARE. The STEPCARE trial is an international, investigator-initiated, randomised trial on three different aspects of standard care after out-of-hospital cardiac arrest. In a 2x2x2 factorial design the effect of continuous sedation vs. minimal sedation, fever management with a device vs. without a device and a higher blood pressure target vs. a lower blood pressure target are compared. The primary outcome of the trial will be survival at 180 days with secondary outcomes including neurological function and health-related quality of life.
  3. To investigate the prognostic value of clinicians' combined perception of inappropriateness of CPR, the clinician's prognostication (functional outcome and quality of life after 6 months) and the added prognostic value of the multimodal ICU neuroprognostication with regard to the long-term composite outcome (alive with a good functional outcome and good quality of life as defined in STEPCARE) above and beyond the prognostic value of clinicians' combined perception of inappropriateness of CPR and the clinician's prognostication within subgroups of initial non-shockable/shockable rhythm.

Statistical analysis Associations between the perception of ICU physicians and ICU nurses regarding appropriateness of CPR, on the one hand, and the ICU clinician's perceived presence of frailty, severe comorbidities, quality of life, as well as objective factors related to the OHCA (shockable rhythm, bystander CPR, witnessed arrest) and clinician characteristics (age, gender, years of experience and professional background), on the other hand, will be estimated (in terms of conditional odds ratios) using a generalised linear mixed effects model (with 'logit' link and a random intercept for center and for patient) to allow statistical inference (estimation of corresponding standard errors and confidence intervals) that correctly accounts for the multilevel structure of the data (i.e. clinicians clustered within patients, patients clustered within centers).

Subsequently, the concordance between clinicians' combined perception of inappropriateness of CPR (A) and the result of the multimodal ICU neuroprognostication (Y) will be assessed by estimating the following predictive metrics with Y being the outcome and A being the predictor:

  • Positive Predictive Value (PPV)
  • Negative Predictive Value (NPV)
  • Sensitivity
  • Specificity
  • Area Under the Receiver-Operator Curve (AUC) The PPV expresses the percentage of poor multimodal ICU neuroprognostications among cases where at least two clinicians perceive CPR to have been inappropriate, while the NPV expresses the percentage of good multimodal ICU neuroprognostications among cases where less than two clinicians perceive CPR to have been inappropriate. Results of the multimodal ICU neuroprognostication will be imputed as 'good' or 'poor' whenever, respectively, patients were discharged alive or died before the multimodal ICU neuroprognostication could be conducted or completed. This enables calculation of the PPV and NPV in the population of patients originally included in the study and gives prospective insight into the extent to which clinicians' combined perception of inappropriateness of CPR in these patients is prognostic for the results of their multimodal ICU neuroprognostication. The sensitivity expresses the percentage of cases where at least two clinicians perceive CPR to have been inappropriate among poor multimodal ICU neuroprognostications, while the specificity expresses the percentage of cases where less than two clinicians perceive CPR to have been inappropriate among good multimodal ICU neuroprognostications. The latter two metrics will be calculated only in patients still hospitalized by the time the multimodal ICU neuroprognostication could be completed. This gives retrospective insight into the extent to which good or poor multimodal ICU neuroprognostication could already be anticipated by clinicians' combined perception of inappropriateness of CPR. Ideally, the multilevel nature of the data will be accounted for when estimating these metrics and their respective confidence intervals.

Subsequently, the prognostic value of clinicians' combined perception of inappropriate CPR and the clinician's prognostication with respect to the primary composite endpoint (alive with a good functional outcome and good quality of life as defined in STEPCARE) will be assessed in terms of the PPV, NPV and AUC. Additionally, the added or incremental prognostic value of the multimodal ICU neuroprognostication above and beyond that of ICU clinicians' combined perception of inappropriate CPR and the clinician's prognostication will be assessed in terms of increase in AUC. More specifically, two logistic regression model will be fitted: a logistic regression model for the primary outcome with clinicians' combined perception of inappropriate CPR, the clinician's prognostication as only predictor (model 1), and a logistic regression model for the primary outcome with clinicians' combined perception of inappropriate CPR, the clinician's prognostication and the result of the multimodal ICU neuroprognostication (and their interaction) as predictors (model 2). The AUCs of these models will be reported, as well as their respective PPV and NPV. AUC of model 2 minus AUC of model 1 will be estimated and used as a metric to quantify the added prognostic value. These analyses will be conducted for the entire study population, as well as in separate subgroups of patients with shockable versus non-shockable initial rhythms. For this analysis, whenever patients were discharged alive or died before the multimodal ICU neuroprognostication could be conducted or completed, results of the multimodal ICU neuroprognostication will be imputed in such a way that their coding is identical to that of the corresponding clinicians' combined perception of inappropriate CPR to reflect the fact that, in such cases, multimodal ICU neuroprognostication can by definition not have any added prognostic value. Ideally, the multilevel nature of the data will be accounted for when estimating these metrics and their respective confidence intervals.

The study will collect additional data apart from the STEPCARE study (NCT 05564754):

ICU doctors and nurses treating the patient in the first 24 hours after ICU admission are requested to complete a short (less than 3 minutes) survey, ideally as soon as possible since we are interested in the predictive value of clinical appraisal of the ICU doctor and ICU nurse.

The survey comprises questions regarding clinician characteristics, perception regarding frailty, quality of life, comorbidities, appropriateness of CPR and prognostication of the outcome 6 months after OHCA.

Keywords
cardiac arrest, out-of-hospital cardiac arrest, cardiopulmonary resuscitation, appropriateness of care, frailty, perception, prognostication, outcome, quality of life, Intensive Care
Medical subject headings
Out-of-Hospital Cardiac Arrest, Heart Arrest, Frailty

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07026773
Study groupRoleWhat they receive
Nurses and doctors working in Intensive Care UnitsNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Composite endpoint of survival, good functional outcome and good quality of life 6 months after OHCA

    Good functional outcome defined as modified Rankin scale 0 - 3; quality of life based on EuroQol-VAS

    Measured: 6 months after return of spontaneous circulation

Secondary outcomes (1)
  1. Assessment of a likely poor neurological outcome based on the multimodal ICU neuroprognostication as performed in the Stepcare study NCT 05564754

    Stepcare criteria for a likely poor neurological outcome are fulfilled yes or no

    Measured: More than 72 hours after randomisation in the Stepcare study NCT 05564754

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jun 2025
  2. Study start18 May 2025
  3. Primary completion30 Dec 2026 (estimated)
  4. Study completion30 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07026773
Sponsor's protocol ID
ONZ-2025-0119
Acronym
VICAP-CPR
Status last verified
Jun 2025
First submitted
10 Jun 2025
Last updated
18 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiac Arrest, Out-Of-Hospital, run by University Hospital, Ghent at 9 sites in 8 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 18 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in Belgium, Austria, Finland, Germany, Italy and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Patrick Druwé, MD, PhD (003293321387, patrick.druwe@uzgent.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite endpoint of survival, good functional outcome and good quality of life 6 months after OHCA (time frame: 6 months after return of spontaneous circulation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in